Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.
Noonepalle S, Shen S, Ptáček J, Tavares MT, Zhang G, Stránský J, Pavlíček J, Ferreira GM, Hadley M, Pelaez G, Bařinka C, Kozikowski AP, Villagra A. Noonepalle S, et al. Among authors: villagra a. J Med Chem. 2020 Sep 24;63(18):10246-10262. doi: 10.1021/acs.jmedchem.0c00567. Epub 2020 Sep 2. J Med Chem. 2020. PMID: 32815366
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells.
Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. Cheng F, et al. Among authors: villagra a. Mol Immunol. 2014 Jul;60(1):44-53. doi: 10.1016/j.molimm.2014.02.019. Epub 2014 Apr 18. Mol Immunol. 2014. PMID: 24747960 Free PMC article.
A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.
Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, Villagra A, Sotomayor EM. Cheng F, et al. Among authors: villagra a. J Immunol. 2014 Sep 15;193(6):2850-62. doi: 10.4049/jimmunol.1302778. Epub 2014 Aug 8. J Immunol. 2014. PMID: 25108026 Free PMC article.
Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation.
Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Woan KV, et al. Among authors: villagra a. Mol Oncol. 2015 Aug;9(7):1447-1457. doi: 10.1016/j.molonc.2015.04.002. Epub 2015 Apr 24. Mol Oncol. 2015. PMID: 25957812 Free PMC article.
Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Knox T, et al. Among authors: villagra a. Sci Rep. 2019 Apr 16;9(1):6136. doi: 10.1038/s41598-019-42237-3. Sci Rep. 2019. PMID: 30992475 Free PMC article.
Functional Analysis of HDACs in Tumorigenesis.
Hadley M, Noonepalle S, Banik D, Villagra A. Hadley M, et al. Among authors: villagra a. Methods Mol Biol. 2019;1983:279-307. doi: 10.1007/978-1-4939-9434-2_17. Methods Mol Biol. 2019. PMID: 31087305 Review.
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
Shen S, Hadley M, Ustinova K, Pavlicek J, Knox T, Noonepalle S, Tavares MT, Zimprich CA, Zhang G, Robers MB, Bařinka C, Kozikowski AP, Villagra A. Shen S, et al. Among authors: villagra a. J Med Chem. 2019 Sep 26;62(18):8557-8577. doi: 10.1021/acs.jmedchem.9b00946. Epub 2019 Sep 4. J Med Chem. 2019. PMID: 31414801
Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells.
Knox T, Sahakian E, Banik D, Hadley M, Palmer E, Noonepalle S, Kim J, Powers J, Gracia-Hernandez M, Oliveira V, Cheng F, Chen J, Barinka C, Pinilla-Ibarz J, Lee NH, Kozikowski A, Villagra A. Knox T, et al. Among authors: villagra a. Sci Rep. 2019 Oct 10;9(1):14824. doi: 10.1038/s41598-019-51403-6. Sci Rep. 2019. PMID: 31597938 Free PMC article.
156 results